Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma, Ewing × TQ-B3525 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Ewing 1 Osteosarcoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1 Chondrosarcoma 1

Interventions

Irinotecan 6 Temozolomide 5 PM 01183 3 X-Rays 2 Vincristine 2 Nivolumab 2 Cyclophosphamide 2 temsirolimus 1 talazoparib 1 surufatinib 1 silmitasertib 1 seclidemstat 1 rubitecan 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 eribulin 1 entrectinib 1 efineptakin alfa 1 dinutuximab 1 copanlisib 1 bempegaldesleukin 1 anlotinib 1 alovudine 1 abemaciclib 1 Zoledronic Acid 1 Trabectedin 1 Topotecan 1 TQ-B3525 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04690725 2020-12-31

TQBSP

Peking University People's Hospital

Phase 1/2 Unknown

Chondrosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡